Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal
-- Payment includes $9.75 million cash and $3.25 million in Imugene Limited ordinary shares-- --The addition of this cash further reinforces Precision’s expected cash runway into the second half of…
Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis
- Out licensed allogeneic CAR T azer-cel receives IND clearance from U.S. FDA DURHAM, N.C. --(BUSINESS WIRE)--Aug. 9, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing…
Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
- Wholly owned programs PBGENE-HBV for Chronic Hepatitis B virus and PBGENE-PMM for m.3243 mitochondrial disease on track for IND and/or CTA submissions in 2024 and 2025, respectively - Expanded…
Precision BioSciences to Participate in Upcoming August Investor Conferences
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 31, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene…
Precision BioSciences to Report Second Quarter Results on August 1, 2024
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 29, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene…
Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 8, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene…
Precision BioSciences Announces its Addition to the Russell Microcap® Index
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 1, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene…
Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025
DURHAM, N.C. --(BUSINESS WIRE)--Jun. 27, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene…
Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness
DURHAM, N.C. --(BUSINESS WIRE)--Jun. 20, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene…
Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress
- PBGENE-HBV specifically cuts HBV DNA without impacting the human genome - PBGENE-HBV was well tolerated across multiple administrations with no off-target editing observed - Preclinical safety data…
Precision BioSciences to Participate in Upcoming June Investor Conferences
DURHAM, N.C. --(BUSINESS WIRE)--May 30, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene…
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
- Wholly owned programs on track for CTA and/or IND submissions - PBGENE-HBV for Hepatitis B virus in 2024 and PBGENE-PMM for primary mitochondrial myopathy in 2025 - First ARCUS in vivo gene editing…
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
DURHAM, N.C. --(BUSINESS WIRE)--May 8, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop…